title: A meta-analysis of the success rate of Helicobacter pylori therapy in Canada.
abstract: OBJECTIVE
  Helicobacter pylori treatment success rates have varied. A systematic review of the success rate of anti- H pylori therapy in Canada was performed.
  
  
  METHODS
  All clinical trials containing Canadian data on the success rate of H pylori treatment were identified using MEDLINE searches, through review of references of retrieved studies and by contacting key investigators. Both randomized and open-label trials were included. Treatment effect size was calculated using a variation of Cochran's Q method.
  
  
  RESULTS
  Seventeen papers met the inclusion criteria. Both triple therapies consisting of a proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole performed well, achieving a success rate of 84% and 82%, respectively. The cure rate of PPI-amoxicillin + metronidazole was 76%. Quadruple therapy consisting of a PPI, bismuth, metronidazole and tetracycline, given for seven to 10 days, achieved a success rate of 87%.
  
  
  CONCLUSIONS
  Both PPI-based triple therapy and quadruple therapy perform well in Canada for the treatment of H pylori infection.
authors.affiliation: Division of Gastroenterology, University of Alberta, Edmonton, Canada.
authors.forename: Christopher
authors.initials: C
authors.lastname: Rodgers
authors.forename: Sander Veldhuyzen
authors.initials: SV
authors.lastname: van Zanten
mesh_terms: D000863:Antacids / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002170:Canada; D002985:Clinical Protocols; D004359:Drug Therapy, Combination; D017506:H(+)-K(+)-Exchanging ATPase / Q000008:administration & dosage*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D017506:H(+)-K(+)-Exchanging ATPase